George Follows
Addenbrooke's Hospital(GB)
Publications by Year
Research Areas
Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research, Viral-associated cancers and disorders, Immunodeficiency and Autoimmune Disorders, CNS Lymphoma Diagnosis and Treatment
Most-Cited Works
- → Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development(2011)2,417 cited
- → Mapping long-range promoter contacts in human cells with high-resolution capture Hi-C(2015)1,072 cited
- → Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial(2020)592 cited
- → Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma(2017)392 cited
- → Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing(2008)381 cited
- → Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial(2020)329 cited
- → Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities(2022)216 cited
- → Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia(2022)194 cited
- → KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype(2014)176 cited
- → Long‐term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study(2019)169 cited